Pyridoxal Phosphate

Phase 3

MEDICURE INC (MCUJF)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Sep '27

MCUJFPhase 3$19M

Pyridoxal Phosphate Phase 3 Est. Readout (MEND-PNPO)

Pyridoxal Phosphate• Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency15

Sep 2027~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency

View Full Landscape

Drug Information

Target Indication

Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency

Clinical Trial

NCT04706013

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

MCUJF

MEDICURE INC

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

(MC-1) Pyridoxal 5'-phosphatePhase 3

Coronary Artery Bypass Graft Surgery

Short TirofibanPhase 2

Myocardial Infarction

(MC-1) Pyridoxal-5'-phosphatePhase 2

Coronary Artery Bypass Graft Surgery

pyridoxal-5'-phosphate with and without ACE inhibitorPhase 2

Diabetes Mellitus Type 2

Long TirofibanPhase 2

Myocardial Infarction

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts